Q4 2025

Filed Mar 12, 2026 · 10-K · 71 days after period end · 0001193125-26-104156

Q4 2025 · 10-K

derived · Computed from the longer spans the company filed.

Revenue

$1.29M

derived−43.1% vs Q4 2024

Net Income

-$50.04M

derivedN/M vs Q4 2024

EPS, diluted—

Same quarter

Metric	Q4 2025derived from reported figures	Q4 2024derived from reported figures	Q4 2023derived from reported figures	Q4 2022derived from reported figures
Revenue	$1.29M	$2.27M	—	$0.00
Net Income	-$50.04M	-$21.20M	-$25.43M	$6.19M

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Korro Bio, Inc. · CIK 1703647 · Engraved from SEC EDGAR